Molina Healthcare, Inc. (MOH) Q3 2022 Earnings Call Transcript
Molina Healthcare, Inc. (NYSE:MOH) Q3 2022 Results Conference Call October 27, 2022 8:00 AM ET
Company Participants
Joe Krocheski - Senior Vice President of Investor Relations
Joe Zubretsky - President and Chief Executive Officer
Mark Keim - Chief Financial Officer
Conference Call Participants
Josh Raskin - Nephron Research
Justin Lake - Wolfe Research
Nathan Rich - Goldman Sachs
Stephen Baxter - Wells Fargo
A.J. Rice - Credit Suisse
Kevin Fischbeck - Bank of America
Steven Valiquette - Barclays
Scott Fidel - Stephens
Calvin Sternick - JPMorgan
Dave Windley - Jefferies
Michael Hua Ha - Morgan Stanley
Joseph France - Loop Capital Markets
Operator
Good day, and welcome to the Molina Healthcare Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note today's event is being recorded.
I would now like to turn the conference over to Joe Krocheski, Senior Vice President, Investor Relations. Please go ahead, sir.
Joe Krocheski
Good morning, and welcome to Molina Healthcare's Third Quarter 2022 Earnings Call. Joining me today are Molina's President and CEO, Joe Zubretsky; and our CFO, Mark Keim. A press release announcing our third quarter earnings was distributed after the market closed yesterday and is available on our Investor Relations website.
Shortly after the conclusion of this call, a replay will be available for 30 days. The numbers to access the replay are in the earnings release. For those who listen to the rebroadcast of this presentation, we remind you that the remarks made are as of today, Thursday, October 27, 2022, and have not been updated subsequent to the initial earnings call.
On this call, we will refer to certain non-GAAP measures. A reconciliation of these measures with the most directly comparable GAAP measures for 2022 can be found in our third quarter 2022 press release. We are unable to provide a reconciliation of our adjusted earnings outlook with GAAP measures for the years beyond 2022 without unreasonable efforts due to the difficulty of predicting the timing and amounts of various items within a reasonable range.
During our call, we will be making certain forward-looking statements, including, but not limited to, statements regarding our 2022 guidance, our long-term growth strategy, our recent RFP awards and RFP submission and the projected revenue and earnings growth associated with these awards, our outlook with regard to both fiscal year 2023 and 2024, our acquisition and M&A activity. The COVID-19 pandemic can redetermination and our current and future competitive earnings power and margins.